Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid

NCT00339131 is registered in ClinicalTrials.gov with Molecular Insight Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00339131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00339131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2006
Completion date
January 31, 2007
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid, paraganglioma, pheochromocytoma